Walleye Capital
RYTM icon

Walleye Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Walleye Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$666K Buy
+5,996
New +$542K ﹤0.01% 2466
2025
Q4 		– Sell
-50,181
Closed -$5.07M – 5042
2025
Q3 		$5.07M Buy
+50,181
New +$4.66M 0.02% 920
2025
Q2 		– Sell
-35,828
Closed -$1.9M – 4970
2025
Q1 		$1.9M Sell
35,828
-108,514
-75% -$6.02M 0.01% 1459
2024
Q4 		$8.08M Buy
+144,342
New +$7.97M 0.02% 773
2023
Q3 		– Sell
-395,541
Closed -$6.52M – 5270
2023
Q2 		$6.52M Buy
395,541
+257,772
+187% +$4.65M 0.02% 591
2023
Q1 		$2.46M Buy
+137,769
New +$3.46M 0.04% 608
2022
Q4 		– Sell
-191,373
Closed -$4.69M – 3573
2022
Q3 		$4.69M Buy
+191,373
New +$3.56M 0.09% 246
2021
Q4 		– Sell
-49,845
Closed -$651K – 2286
2021
Q3 		$651K Buy
+49,845
New +$761K 0.02% 670

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Walleye Capital's RYTM Position: Q2 2026 in Review

Walleye Capital opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 5,996 shares worth $666K. The stake represents ﹤0.01% of the portfolio and ranks #2466 among its holdings. This is a return to the name: Walleye Capital previously reported a position in RYTM as recently as Q3 2025.

Walleye Capital first reported a position in RYTM in Q3 2021 and has held it in 8 quarters since. The position peaked at $8.08M in Q4 2024. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Walleye Capital held 5,996 shares of Rhythm Pharmaceuticals worth $666K as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Walleye Capital position in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2466 holding.
  • Walleye Capital first reported a position in Rhythm Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
  • Walleye Capital's Rhythm Pharmaceuticals position peaked at $8.08M in Q4 2024.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.